Anavex Life Sciences Corp (AVXL)
4.075
-0.06
(-1.57%)
USD |
NASDAQ |
May 31, 16:00
4.065
-0.01
(-0.25%)
After-Hours: 20:00
Anavex Life Sciences Enterprise Value: 205.53M for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 205.53M |
| May 30, 2024 | 211.03M |
| May 29, 2024 | 189.87M |
| May 28, 2024 | 205.10M |
| May 24, 2024 | 199.18M |
| May 23, 2024 | 213.57M |
| May 22, 2024 | 241.50M |
| May 21, 2024 | 228.80M |
| May 20, 2024 | 235.58M |
| May 17, 2024 | 245.73M |
| May 16, 2024 | 241.50M |
| May 15, 2024 | 240.65M |
| May 14, 2024 | 225.42M |
| May 13, 2024 | 198.33M |
| May 10, 2024 | 183.10M |
| May 09, 2024 | 189.02M |
| May 08, 2024 | 174.63M |
| May 07, 2024 | 185.64M |
| May 06, 2024 | 185.64M |
| May 03, 2024 | 186.48M |
| May 02, 2024 | 178.87M |
| May 01, 2024 | 172.94M |
| April 30, 2024 | 169.56M |
| April 29, 2024 | 169.56M |
| April 26, 2024 | 151.78M |
| Date | Value |
|---|---|
| April 25, 2024 | 144.07M |
| April 24, 2024 | 145.75M |
| April 23, 2024 | 168.32M |
| April 22, 2024 | 168.32M |
| April 19, 2024 | 176.68M |
| April 18, 2024 | 178.36M |
| April 17, 2024 | 200.93M |
| April 16, 2024 | 205.11M |
| April 15, 2024 | 214.31M |
| April 12, 2024 | 219.75M |
| April 11, 2024 | 232.71M |
| April 10, 2024 | 219.33M |
| April 09, 2024 | 227.69M |
| April 08, 2024 | 227.69M |
| April 05, 2024 | 230.20M |
| April 04, 2024 | 235.21M |
| April 03, 2024 | 246.92M |
| April 02, 2024 | 240.23M |
| April 01, 2024 | 280.37M |
| March 28, 2024 | 274.19M |
| March 27, 2024 | 271.72M |
| March 26, 2024 | 253.66M |
| March 25, 2024 | 229.85M |
| March 22, 2024 | 238.88M |
| March 21, 2024 | 275.83M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
93.44M
Minimum
Aug 05 2019
2.014B
Maximum
Jun 28 2021
538.09M
Average
495.06M
Median
Aug 28 2023
Enterprise Value Benchmarks
| Ventyx Biosciences Inc | 35.81M |
| Checkpoint Therapeutics Inc | 58.77M |
| Amicus Therapeutics Inc | 3.052B |
| Insmed Inc | 8.750B |
| InfuSystems Holdings Inc | 181.16M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -10.55M |
| Total Expenses (Quarterly) | 12.05M |
| EPS Diluted (Quarterly) | -0.13 |
| Earnings Yield | -12.52% |